Aspira Women’s Health Inc. (NASDAQ: AWH) shares jumped Friday as the bio-analytical-based women’s health company focused on gynecologic disease, today announced that one of the nation’s top national health insurance companies with over 80 million lives worldwide has agreed to extend coverage to OvaWatchSM, Aspira’s new ovarian cancer test launched by the Company in December 2022. The plan has covered the Ova1Plus® test for its members for the past several years and this coverage decision ensures OvaWatch will be provided on an in-network basis for the plan’s members minimizing their out of pocket expenses. The coverage decision was based on the latest published evidence demonstrating the clinical validation of OvaWatch.
“We are very pleased to see one of the largest and most progressive health plans in the country quickly recognize the value that OvaWatch brings to patients and clinicians in better managing ovarian cancer risk, and offer it to their members on an in-network basis,” said CEO Nicole Sandford. “This coverage decision further validates the important role our OvaSuite product portfolio plays in the clinical management of women with adnexal masses.”
OvaWatch is a non-invasive, multivariate index assay intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the right treatment for the right patient at the right time.
Shares in AWH gained 3.6 cents, or 10.3%, to 39 cents.
Related Stories
